Keros Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track designation for KER-050 for the treatment of anemia in adult patients with very low-, low-, or intermediate-risk myelodysplastic syndromes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KROS:
- Keros Therapeutics initiated with a Not Rated at Goldman Sachs
- Keros Therapeutics Updates Corporate Presentation Online
- Keros Therapeutics CMO Simon Cooper Resigns
- Keros Therapeutics CEO to Speak at Global Biopharma Conference
- Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
